Nasdaq · CIK 0001649904
RYTM RHYTHM PHARMACEUTICALS, INC.
A
95 / 100
Material weaknesses
1
Restatements
0
Auditor changes
0
Late filings
0
Quarters with open weakness
1
Remediations
1
Deductions
20
Remediation credit
15
Trailing 24 months from 2024-11-07. Rubric v1. How this is scored.
Disclosures, in the company's words
“our management concluded that these control deficiencies constitute a material weakness and that our internal control over financial reporting was not effective as of December 31, 2023.”
“We previously identified a material weakness in internal control related to ineffective information technology general controls, or ITGCs, in the areas of user access and program change management over our key accounting and reporting information technology, or IT, system.”
Remediation disclosed
- 10-Q · filed 2026-11-03 · source filing ↗
“Our management designed and implemented new controls and measures to remediate this material weakness, and management has concluded that the material weaknesses described above have been remediated.”
Filings read
- 10-Q · 2026-11-03read
- 10-Q · 2026-08-04queued
- 10-Q · 2026-05-05queued
- 10-K · 2026-02-26queued
- 10-Q · 2025-11-04queued
- 10-Q · 2025-08-05queued
- 8-K · 2025-07-11queued
- 10-Q · 2025-05-07queued
- 10-K · 2025-02-28queued
- 10-Q · 2024-11-06queued
Think something here is wrong? Request a correction. Open corrections hide the affected disclosure until resolved.